Skip to main content

Table 4 Ongoing intervention studies aiming to reduce cardiovascular disease in cancer patients; only actively recruiting studies are mentioned (accessed 2021-03-22)

From: Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer ID Population Intervention Primary endpoint Estimated enrollment
NCT03964142 BC pts. treatment with anthracyclines and / or anti-HER-2 antibodies comprehensive cardiac rehabilitation program including supervised exercise training Change in left ventricular systolic function quantified by left ventricular ejection fraction and global longitudinal strain by transthoracic echocardiography 340
NCT04476576 hemato-oncological diseases that initiate chemotherapy Aerobic exercise Vs Flexibility exercise Change in systolic longitudinal strain (exercise of flexibility and balance). [Time Frame: 6 months] 38
NCT03850171 Pts with breast cancer or lymphoma scheduled for anthracycline-based chemotherapy Exercise Training Changes from baseline in left ventricular (LV) global longitudinal strain (GLS) [Time Frame: week 13] 120
NCT03787966 BC pts. scheduled for surgery and adjuvant chemotherapy Exercise training before or before and after medical treatment Left ventricular ejection fraction [Time Frame: Participants will be followed over 12 months] 100
NCT03711110 Elderly pts. Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myelom Intensive cardiovascular monitoring All-cause mortality [Time Frame: Two (mid-term analysis) and 5 years of follow-up] 514
NCT03186404 Pts with BC, lymphoma, leukemia or sarcoma scheduled for anthracycline-based chemotherapy Atorvastatin Cardiac MRI measured LVEF within 4 weeks of anthracycline completion 112
NCT04023110 breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab Carvedilol Left Ventricular Ejection Fraction (LVEF) [Time Frame: up to 24 months 110
NCT03265574 Pts with BC and lymphoma treated with anthracyclines Enalapril Cardiac troponin T release [Time Frame: One month after last dose of anthracycline 170
NCT03650205 cancer pts. treated with anthracyclines Ivabradine Ventricular function [Time Frame: 365 days after randomization]
Reduction in global longitudinal strain of at least 10% (GLS)
NCT04030546 cancer pts. treated with anthracyclines Ivabradine Change in left venticular dysfunction by global longitudinal strain (GLS). [Time Frame: 1, 3 and 6 months]
Change in global longitudinal strain (GLS) at least by 3%.
NCT04429633 breast cancer patients treated with adjuvant trastuzumab. Candesartan Left ventricular ejection fraction (LVEF) [Time Frame: at months 3,6,9,12,18] 136
NCT02818517 Two cohorts, one prospective group will include all oncologic patients who will be evaluated in the cardio-oncology clinic ACE inhibitors or beta blockers ECho-global strain [Time Frame: 2 years 1000
NCT04092309 Pts undergoing Hematopoietic Stem Cell Transplantation Sacubitril-Valsartan Left Ventricular Function, Global Longitudinal Strain, arterial stiffness, glycocalyx thickness
[Time Frame: 2 years]
NCT02943590 Pts with newly diagnosed NHL and HL, anthracycline-based therapy Atorvastatin Left ventricular Ejection Fraction (LVEF) [Time Frame: 12 months] 270
NCT04632407 BC pts. during adjuvant chemotherapy Dietary Supplement: Flax “milk”Dietary Supplement: Oat fibre “milk” Left ventricular ejection fraction (LVEF) change [Time Frame: 1 year] 60
NCT03934905 BC pts. neoadjuvant treatment incl doxorubicin sulforaphane Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies [Time Frame: At baseline and 1 year from baseline assessment.] 70
NCT04361240 Breast cancer radiotherapy Radiation: Proton vs Photon Radiation Change in echocardiography derived LVEF from baseline 155